Cancer Letters · 2022 · 55 citations · 41 references
MedicineImmunologyOncologyCancer ImmunologyChemotherapyTumor MicroenvironmentCancer ImmunotherapyMacrophage BiologyTargeted Cancer TherapyTumor Immune MicroenvironmentTumor Microenvironment ModulationTumor-associated MacrophagesCancer-associated MacrophagesColony-stimulating Factor 1 Receptor TargetingPd-l1 BlockadeTransforming Growth Factor Beta-mediated Immune SuppressionTumor-associated Macrophage Reprogramming
41
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
H. Borghaei, L. Paz-Ares, Leora Horn et al. · New England Journal of Medicine · 2015 · 9.5K citations · Full text
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert J. Motzer, Bernard Escudier, Saby George et al. · New England Journal of Medicine · 2015 · 5.9K citations · Full text
Medicine, Oncology, Pharmacotherapy +17
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan, Shannon J. Turley, Dorothee Nickles et al. · Nature · 2018 · 5.5K citations
Life Sciences, Immunology, Oncology +16
Colorectal cancer statistics, 2017
Rebecca L. Siegel, Kimberly D. Miller, Stacey A. Fedewa et al. · CA A Cancer Journal for Clinicians · 2017 · 3.9K citations · Full text
Leonard B. Saltz, Stephen Clarke, Eduardo Díaz‐Rubio et al. · Journal of Clinical Oncology · 2008 · 3K citations · Full text
Medicine, Oncology, Pharmacology +12